Press Release: Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and lisavanbulin at AACR Annual Meeting
Basel, Switzerland, April 13, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer
Basel Stadt United States M El Shemerly F Bertoni Avanbulin Laurenz Kellenberger P Mcsheehy Derazantinib
Source: finanznachrichten.de